AC
TRVI icon

Armistice Capital’s Trevi Therapeutics TRVI Stock Holding History

Armistice Capital’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,988,000
Closed -$18.8M – 270
2025
Q1 		$18.8M Buy
+2,988,000
New +$14.3M 0.28% 67
2022
Q4 		– Sell
-864,000
Closed -$1.33M – 235
2022
Q3 		$1.33M Buy
864,000
+448,000
+108% +$1.47M 0.02% 133
2022
Q2 		$1.17M Buy
+416,000
New +$1.02M 0.02% 123
2022
Q1 		– Sell
-1,512,344
Closed -$1.18M – 184
2021
Q4 		$1.18M Buy
+1,512,344
New +$1.59M 0.02% 127

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Armistice Capital's TRVI Position: Q2 2025 in Review

Armistice Capital sold out of Trevi Therapeutics (TRVI) in Q2 2025, closing a stake of 2,988,000 shares — an estimated $18.8M sold.

Armistice Capital first reported a position in TRVI in Q4 2021 and held it in 4 quarters. The position peaked at $18.8M in Q1 2025. 153 funds tracked by Wall St. Rank hold TRVI as of Q2 2025.

  • Armistice Capital reported no remaining Trevi Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Armistice Capital sold 2,988,000 Trevi Therapeutics shares in Q2 2025, an estimated $18.8M.
  • Armistice Capital first reported a position in Trevi Therapeutics in Q4 2021 and held it in 4 quarters.
  • Armistice Capital's Trevi Therapeutics position peaked at $18.8M in Q1 2025.
  • 153 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2025.

Based on Armistice Capital's 13F filing for Q2 2025, filed 14 Aug 2025.